Latest Corporate News News
Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone)
Shionogi & Co., Ltd. announced the completion of its acquisition of global rights to RADICAVA from Tanabe Pharma for a lump sum of USD 2.5 billion, with potential additional royalties. The deal integrates over 100 team members and adds approximately USD 700 million in annual sales, expected to be accretive in fiscal 2026.
CEO Isao Teshirogi emphasized commitment to ALS patients and future rare disease launches.
Gilead Extends Tender Offer to Acquire Arcellx
Gilead Sciences has extended its tender offer to acquire Arcellx, previously set to expire just after 11:59 p.m. ET on April 2, 2026. The new expiration is at 5:00 p.m. ET on the extended date.
This move aims to facilitate the acquisition process amid ongoing negotiations.
Aspire Securities Holds Daily Meeting for Egyptian Stock Exchange Session
Aspire Securities and Bonds Trading Company conducted its daily morning technical analysis meeting for the Egyptian Stock Exchange session on April 2, 2026. The session covers market trends and trading insights.
This reflects ongoing corporate activity in regional financial markets.
Shionogi Establishes Strong Platform in Rare Disease Space with RADICAVA
Following the RADICAVA acquisition, Shionogi now holds full global rights to RADICAVA ORS and IV formulations for ALS treatment. Integration is fully operational from day one to ensure continuity of care.
The move supports Shionogi's 2030 Vision for patient health.
Gilead's Arcellx Acquisition Advances with Tender Extension
The extension provides additional time for shareholders to tender shares in Gilead's bid for biotech firm Arcellx. This is part of Gilead's strategy to expand in innovative therapies.
Details on the offer terms remain consistent with prior announcements.
Shionogi Inc. President Reaffirms Commitment to ALS Community
Nathan McCutcheon, President and CEO of Shionogi Inc., highlighted RADICAVA's importance for ALS patients post-acquisition. The company pledges ongoing support and innovation in care.
Over 100 team members from Tanabe Pharma America have joined Shionogi.
Egyptian Market Analysis: Aspire Securities Session Update
Aspire's April 2 session focuses on technical analysis amid global market volatility. Discussions include bonds and securities trading strategies.
This corporate event underscores active engagement in emerging markets.
RADICAVA Deal Terms: $2.5B Upfront, Royalties on Future Sales
Shionogi paid USD 2.5 billion upfront via Shionogi Inc. for RADICAVA rights in major regions. Additional royalties apply based on future sales conditions.
Intellectual property and sales rights are now fully with Shionogi.
Gilead Positions for Biotech Growth via Arcellx Deal
The tender offer extension signals strong intent to close the Arcellx acquisition soon. Gilead aims to bolster its portfolio with Arcellx's technologies.
Market watchers await shareholder response.
Shionogi's RADICAVA Acquisition Boosts Fiscal 2026 Outlook
The transaction is immediately accretive, adding $700M in global annual sales to Shionogi. This strengthens commercial platform for rare diseases.
Osaka-based firm eyes future launches.
Corporate Spotlight: Shionogi's ALS Treatment Expansion
Shionogi's full control of RADICAVA enhances supply chain for ALS patients worldwide. CEO Teshirogi noted alignment with long-term vision.
Deal announced originally in December 2025.
Regional Finance: Aspire's Stock Exchange Briefing
Daily Aspire meeting on 02-04-2026 provides key insights for investors. Covers technicals for Egyptian equities and bonds.
Highlights corporate resilience in trading sessions.